Holding(s) in Company

RNS Number : 4777G

Verona Pharma PLC

30 May 2017

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESⁱ


1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ⁱⁱ		Verona Pharma plc
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights			X
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the notification obligation: ⁱⁱⁱ	Vivo Ventures VII, LLC
4. Full name of shareholder(s) (if different from 3.):^iv	Vivo Ventures fund VII, LP Vivo Ventures VII Affiliates Fund, LP
5. Date of the transaction and date on which the threshold is crossed or reached: ^v	April 28, 2017
6. Date on which issuer notified:	April 28, 2017
7. Threshold(s) that is/are crossed or reached: ^{vi, vii}	9.84% to 9.14% Change at Combined Interest Level

8. Notified details:

A: Voting rights attached to shares ^{viii, ix}

Class/type of
shares

if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of voting rights ^x

Direct

Direct ^xi

Indirect ^xii

Direct

Indirect

Ordinary

GB00B06GSH43

5,047,877

4.83%

ADS

US925050106

4,507,040

4.31%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date ^xiii

Exercise/
Conversion Period ^xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments ^{xv, xvi}

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date ^xvii

Exercise/
Conversion period ^xviii

Number of voting rights instrument refers to

% of voting rights ^{xix, xx}

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

9,554,917

9.14%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: ^xxi
Vivo Ventures VII, LLC is the general partner of both Vivo Ventures Fund VII, LP (VV Fund VII) and Vivo Ventures VII Affiliates Fund, LP. (Affiliates Fund VII). Accordingly, Vivo Ventures VII, LLC may be deemed to have indirect beneficial ownership of shares of the Issuer directly owned by VV Fund VII and Affiliates Fund VII. As of the date of this filing, VV Fund VII and Affiliates Fund VII beneficially own 9,351,110 and 203,807 shares of Common Stock respectively.
Proxy Voting:
10. Name of the proxy holder:		See Section 4
11. Number of voting rights proxy holder will cease to hold:
12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:
14. Contact name:	Vivo Capital, LLC Attn: Cinthia Sheu
15. Contact telephone number:	+1-650-688-0818

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLPGUUWAUPMPUB